Intellia Therapeutics Inc is trading at $13.47 (8.6% down) as investors lock in profits following yesterday’s 13% surge and shift focus back to the company's fundamental financial challenges.
- Yesterday's rally was triggered by a Zacks note highlighting a high statistical chance of an earnings beat, which reignited debate over the company's $1.8 billion valuation as a pre-revenue biotech.
- Today's pullback is driven by a renewed focus on cash burn and the dilution overhang remaining from a late-April equity offering.
- Recent post-earnings analysis has also underscored concerns regarding execution timelines and the long-term path to commercialization.